The effect of pulsed light therapy on meibomian gland dysfunction patients
- Conditions
- Diseases of the eye and adnexa
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 30
1.Adult over 19 years of age
2.Patient diagnosed with meibomian gland dysfunction
3.Fitzpatrick skin type I-IV
4.Those who voluntarily agreed to participate in the study
1.Fitzpatrick skin type V-VI
2.Sun or artificial tanning within 4 weeks prior to the study participation
3.Dermatologic condition that does not allow to receive light therapy
4.Ocular or eyelid surgery within 6 months prior to study participation
5.Ocular infection or inflammation
6.Precancerous lesion or skin cancer in the treatment area
7.Systemic infection or immunosuppressive status
8.Medical conditions associated with photosensitivity such as herpes simplex virus infection, systemic lupus erythematosis and porphyria
9.Medications which can cause photosensitivity such as isoretinoin, tetracycline, and St. John’s warts
10.Radiotherapy history within 1 year prior to study participation, or planned radiotherapy within 8 weeks from study conclusion
11.Chemotherapy history within 8 weeks prior to study participation, or planned chemotherapy within 8 weeks from study conclusion
12.Topical medication use on the treatment area or a new drug history within 3 months prior to study participation
13.Change in previous drug regimen within 3 months prior to study participation
14.Pregnant or lactating
15.Monocular
16.Those who the investigators consider inappropriate to participate in the study
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in meibomian gland function
- Secondary Outcome Measures
Name Time Method Change in tear cytokine;Change in corneal and conjunctival staining;Change in tear break-up time;Change in Ocular Surface Disease Index